Acquired molecular changes can promote the spreading of primary tumor cells to distant tissues. In this issue of Cell, Roe et al. show that metastatic progression of pancreatic cancer involves largescale enhancer reprogramming by Foxa1, which activates transcriptional program specifying early endodermal stem cells.
Cancer cells navigate numerous hurdles in order to establish metastasis: traversing blood vessels, surviving in the circulation, and colonizing and propagating at foreign habitats from single cells or small groups of cells. The molecular programs that endow cells with the hardiness and plasticity to metastasize may vary considerably in different contexts. In some cancer types, mutations of oncogenes or tumor suppressors have been detected in metastatic tumor nodules while remaining undetectable at the primary site (JamalHanjani et al., 2017) . By contrast, other malignancies such as pancreatic ductal adenocarcinoma (PDA) appear to lack metastasis-specific driver mutations (Makohon-Moore et al., 2017) . While particular genetic alterations that both promote earlier stages of PDA and are associated with higher propensity for metastasis have been identified (Weissmueller et al., 2014; Whittle et al., 2015; Kugel et al., 2016) , elucidating the circuitry distinguishing metastases from the originating tumor remains a fascinating puzzle. In this context, recent studies uncovered linked metabolic and epigenetic adaptations, and changes in tumor-stroma interactions, as key differences between primary and metastatic disease in PDA (Costa-Silva et al., 2015; Aiello et al., 2016; McDonald et al., 2017) .
Motivated by these observations in PDA, in this issue of Cell, Roe et al. (2017) investigate whether other, non-genetic acquired traits could underlie the metastatic phenotype. They hypothesized that metastatic spread of PDA may be associated with changes in the chromatin landscape, with a particular focus on enhancer elements that are central to the control of cell states. To test their hypothesis, the authors utilized 3D-organoid cultures derived from a well-established genetically engineered mouse (GEM) model driven by oncogenic Kras G12D and Tp53 R172H mutations, which are common in human PDA. Matched organoids isolated from primary pancreatic tumors (T) and metastases (M) from the same animals showed marked differences upon reimplantation into recipient mice, with the M organoids both growing faster at the primary site of injection and exhibiting enhanced ability to form distant tumors in various surrogate assays for metastatic potential. Having established that T and M organoids have hard-wired differences in tumorigenic phenotypes, the authors next utilized this elegant system to map profiles of active enhancers marked by acetylation at histone H3 lysine 27 (H3K27ac) and mono-methylation at histone H3 lysine 4. They noted significant differences in activated enhancers in the M organoids compared to T organoids. Examination of the set of 857 enhancers showing > 10-fold increased H3K27ac in the M organoids (designated GAIN regions) revealed strong enrichment for consensus DNA binding sites of a number of transcription factors (TFs), including those in the AP1, Sox, and Forkhead families. The authors focused on Forkhead box protein A1 (Foxa1), given its elevated expression in M cultures. Notably, Foxa1 is required for specification of the foregut endoderm (from which the primitive pancreas originates), serving as a ''pioneer factor'' that can bind condensed, transcriptionally silenced chromatin and render such regions competent for additional TF recruitment and transcriptional activity. Indeed, the GAIN regions were enriched for genes upregulated in in vitro differentiation of embryonic stem cells to foregut endoderm. Gain-and loss-of-function studies confirmed that Foxa1 induces both H3K27ac at GAIN loci and expression of the associated foregut endoderm genes. Of practical interest, these signatures were partially lost when 2D cell lines were studied, validating the use of the organoid models. Moreover, ectopic overexpression of Foxa1 in T organoids rendered them more proliferative and migratory in vitro and increased both primary tumor growth and metastatic properties in vivo, whereas knockdown of Foxa1 in M cells impaired tumor growth. Based on these observations, the authors conclude that metastasis in the GEM model involves activation of a Foxa1-regulated endoderm-like epigenetic state specifically in metastatic tumor nodules (Figure 1) . Consistent with the relevance of this program to human PDA metastasis, the authors showed in human specimens that FOXA1 mRNA levels were increased in metastasis compared to primary tumors. Moreover, in primary tumor organoids, FOXA1 levels were higher when isolated from patients with locally invasive or metastatic disease than from patients with lower grade disease. Finally, the examination of baseline levels of FOXA1 and ectopic overexpression studies indicated that FOXA1 activates a comparable set of enhancers as seen in the mouse.
These studies are conceptually appealing, indicating that the metastatic program involves a resetting of the cell to a more primitive, developmentally plastic, differentiation state, driven by a largescale change in the active enhancer landscape. This work raises a number of interesting questions. First, while enhancers are known to be important for specifying transcriptional programs that drive cell fate changes, it is intriguing that a large-scale shift of enhancer usage is particularly critical for PDA metastasis. It remains to be explored whether this phenomenon plays a role in other cancer types and, if so, whether it might involve similar themes of pioneer transcription factor recruitment and partial reversion to earlier stages of differentiation. Second, it is worth noting that in addition to the enhancer signature, the M organoids showed a key genetic alteration that distinguished them from T organoids, namely specific loss of the remaining wild-type allele of p53, which likely contributes to the metastatic phenotype. While the authors show that p53 inactivation in T organoids does not acutely induce Foxa1 mRNA expression or provoke the Foxa1-driven enhancer signature, it is possible that in vivo p53 loss could create a permissive setting for Foxa1 activation. Overall, the program controlled by p53 in this context, as well as the molecular switch that underlies initial Foxa1 induction, warrants investigation. There are a number of mechanistic questions that also emerge from these studies. For example, the authors report that their metastatic models did not exhibit a typical epithelial-to-mesenchymal (EMT) transition, which has previously been implicated in metastasis (Rhim et al., 2012; Aiello et al., 2016 ). However, it remains possible that a transient activation of the EMT may have contributed to specific stages during metastatic progression, and hence, it will be interesting to assess whether Foxa1 can increase the propensity for EMT when appropriate stimuli are present. Other outstanding questions are how exactly FOXA1 drives the enhancer reprogramming process and what specific FOXA1 target genes drive growth and metastasis, which could inform treatment approaches, as well as better understanding of cancer mechanisms. In addition, the authors indicate that chromatin accessibility in FOXA1-target genes is already established in primary tumors, and they suggest that such genes are ''poised'' for subsequent activation. Yet, a known mark of poised enhancers, H3K4me1, is only observed in the M organoids, raising the question as to what extent these enhancers are poised in the earlier stages of the disease.
Finally, the role of this program in human PDA requires further study, since the authors report notable differences between the organoid model and human specimens. In particular, FOXA1 increases and the GAIN signature were seen in primary human PDA samples, rather than being restricted to metastasis as in the GEM model. In addition, the authors never examined chromatin profiles from in vivo samples, which is a potential caveat to the reported findings from organoids and further emphasizes the need for additional validation of human relevance. As matched human primary and metastasis samples start to become more available, it should be possible to get a definitive view of the epigenetic features, including the active enhancer landscape, of PDA metastasis. Notwithstanding these questions, these new studies highlight the roles that enhancers and chromatin dynamics play in advanced cancer, providing further argument that modulating chromatin may be considered within the arsenal to treat this devastating disease.
Figure 1. Enhancer Reprogramming in Pancreatic Cancer Metastasis
A schematic diagram depicting a series of events, as seen during pancreatic cancer progression. While specific genetics events have been described for normal pancreatic epithelial cells to give rise to primary pancreatic adenocarcinoma, here, the authors identified a FOXA1-dependent epigenetic reprogramming of enhancers as a major mechanism behind the progression of primary tumors to metastatic lesions. Such reprogramming activates genes related to foregut endoderm development, suggesting that these metastatic lesions undergo a retrograde developmental transition.
